{"result_id": "012011", "URL": "https://www.ageofautism.com/2022/01/as-omicron-surges-fdas-vaccine-strategy-called-into-question.html", "timestamp": "2023-04-25 11:56:17 CEST+0200", "meta": {"description": "In other words, from a risk/benefit perspective it is more logical to continue monoclonal antibody infusions, even if they are only marginally effective, and halt childhood vaccinations immediately. The CDC\u2019s and FDA\u2019s mystifying position can only be the result of...", "lang": "en", "keywords": "", "favicon": "", "canonical": "https://www.ageofautism.com/2022/01/as-omicron-surges-fdas-vaccine-strategy-called-into-question.html", "encoding": "utf-8"}, "image": null, "domain": "www.ageofautism.com", "title": "As Omicron Surges, FDA\u2019s Vaccine Strategy Called Into Question", "cleaned_text": "In other words, from a risk/benefit perspective it is more logical to continue monoclonal antibody infusions, even if they are only marginally effective, and halt childhood vaccinations immediately.\n\nThe CDC\u2019s and FDA\u2019s mystifying position can only be the result of their systematic denial of any possibility of vaccine adverse events despite the enormous and mounting evidence to the contrary.\n\nThe Omicron variant is the predominant COVID-19 strain in the U.S., prompting a pause in the distribution of certain ineffective monoclonal antibody therapies. Yet the push for vaccines, also ineffective against the variant, continues unabated.\n\nThe first case of Omicron in the U.S. was reported on Dec. 1, 2021. As of Dec. 25, 2021, the Centers for Disease Control and Prevention (CDC) estimates Omicron accounts for 58.6% of SARS-CoV-2 infections in the U.S.\n\nOmicron\u2019s rapid emergence is indicative of the variant\u2019s increased transmissibility and the lack of efficacy vaccines have against this strain.\n\nThe predominance of the Omicron variant prompted the Office for the Assistant Secretary of the U.S. Department of Health and Human Services (HHS) to pause allocation of two commonly used monoclonal Antibody therapy combinations \u2014 bamlanivimab/etesevimab (Eli Lilly) and REGN10933/REGN10987 (Regeneron) \u2014 to regions of the country that have greater than 80% prevalence of the Omicron variant.\n\nAccording to HHS, \u201cThese two products are not expected to be effective in patients infected with the Omicron variant\u2026\u201d", "opengraph": {"title": "As Omicron Surges, FDA\u2019s Vaccine Strategy Called Into Question", "site_name": "AGE OF AUTISM", "type": "blog", "url": "https://www.ageofautism.com/2022/01/as-omicron-surges-fdas-vaccine-strategy-called-into-question.html", "description": "In other words, from a risk/benefit perspective it is more logical to continue monoclonal antibody infusions, even if they are only marginally effective, and halt childhood vaccinations immediately. The CDC\u2019s and FDA\u2019s mystifying position can only be the result of...", "image": "https://www.rescuepost.com/.a/6a00d8357f3f2969e20282e13cf691200b-600wi"}, "tags": [], "tweets": [], "movies": [], "links": ["https://www.rescuepost.com/.a/6a00d8357f3f2969e20282e13cf691200b-pi", "https://childrenshealthdefense.org/defender/vaers-cdc-covid-vaccine-injuries-fda-pfizer-booster-kids/", "https://openvaers.com/covid-data", "https://www.npr.org/sections/coronavirus-live-updates/2021/12/01/1059835937/omicron-us-first-case", "https://covid.cdc.gov/covid-data-tracker/#variant-proportions", "https://childrenshealthdefense.org/defender/pfizer-vaccine-less-effective-against-omicron/", "https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/update-29Dec12.aspx", "https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-bamlanivimab-and-etesevimab-monoclonal-antibody-therapy-post-exposure-prophylaxis", "https://www.fda.gov/media/151863/download"], "authors": [], "publish_date": null}